AAPL 248.58 0.8479% MSFT 453.21 0.9399% NVDA 137.4648 -1.3245% GOOGL 194.46 -0.4811% GOOG 195.97 -0.3762% AMZN 229.82 -0.1911% META 630.9 -0.2813% AVGO 179.8499 -1.8287% TSLA 420.25 -1.0641% TSM 192.5975 -0.715% LLY 781.77 -1.7914% V 314.5 0.2263% JPM 241.66 -0.7679% UNH 520.37 -2.4666% NVO 109.19 -2.2383% WMT 95.08 0.1264% LVMUY 135.51 -0.14% XOM 112.375 0.4065% LVMHF 682.0 0.3561% MA 533.22 -0.2301%
Royalty Pharma plc
Company Overview: Royalty Pharma plc (NASDAQ: RPRX) engages in the acquisition of biopharmaceutical royalties and the provision of financial support for innovation within the biopharmaceutical sector. The company establishes partnerships with pioneers in this field, including those affiliated with academic institutions, research hospitals, and non-profit organizations, extending its reach from small to mid-cap biotechnology firms to large global pharmaceutical corporations.
As per our previous US Daily report published on ‘RPRX’ on 18th September 2023, Kalkine provided an ‘Buy’ stance on the stock at USD 27.77 based on “price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis” and the stock price has now moved by ~4.61% since then.
Noted below are the details of support and resistance levels provided in our previous report:
RPRX’s Daily Chart
Considering the current trading levels, risks associated, and volatile market conditions on the back of higher interest rates, an ‘Sell’ rating is assigned to the “RPRX” at the closing market price of USD29.05 (as of 11 April 2024).
Note: This report may be updated with details around fundamental and technical analysis, price/ chart in due course, as appropriate
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is April 11, 2024. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.
Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’
Kalkine Equities LLC provides general information about companies and their securities. The information contained in the reports, including any recommendations regarding the value of or transactions in any securities, does not take into account any of your investment objectives, financial situation or needs. Kalkine Equities LLC is not registered as an investment adviser in the U.S. with either the federal or state government. Before you make a decision about whether to invest in any securities, you should take into account your own objectives, financial situation and needs and seek independent financial advice. All information in our reports represents our views as at the date of publication and may change without notice.
Kalkine Media LLC, an affiliate of Kalkine Equities LLC, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
US 
AU
UK
CA
NZ
Please wait processing your request...